Search
Nov 7
Texas Life Science Forum: NKILT Therapeutics is emerging into the in-vivo proof of concept stage of testing its HLA-G targeting cell therapy
CEO Raphaël Ognar describes the progress his company has made over the last year and previews data it will be presenting at SITC and ASH....
Nov 7, 2023
The CEO of NKILT Therapeutics talks about using NK cells to target the HLA-G pathway
Raphaël Ognar discusses the results we have seen in the NK space over recent years.
.png){kind=logo}
